Adjuvant gemcitabine and cisplatin (GC) for locally advanced cancer of the bladder after radical cystectomy: A USC experience with molecular correlates.


4639 Background: Invasive bladder cancer has a 50% mortality rate. Adjuvant chemotherapy is used to try to improve survival, but is of unproven benefit. GC and MVAC have similar response rates and survival in the metastatic setting, with GC having less toxicity (JCO 17: 3068). We have used the GC regimen for patients with high grade bladder cancer with poor… (More)


  • Presentations referencing similar topics